Searching for keyword:"Metabolic Syndrome"

1,288 results
Record publications over time
Ironsift results are limited for unregistered users. Register or log in to see all records.

US Clinical Trial NCT00452192 – NIH – Mar 26, 2007

Detailed Analysis of the Effects of Telmisartan on Renal Perfusion in Patients With Metabolic Syndrome

see above
Full record

US Clinical Trial NCT00307411 – NIH – Mar 27, 2006

Effects of Growth Hormone on Body Fat Distribution, Insulin Action and Cardiovascular Risk Factors in Middle-Aged Men With Metabolic Syndrome

Metabolic syndrome, a constellation of glucose intolerance, hypertension, dyslipidemia, obesity, pro-inflammatory and prothrombotic state culminating to development of premature cardiovascular diseases is a serious public health problem with signifi...
Full record

US Clinical Trial NCT00189085 – NIH – Sep 12, 2005

The Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Dysfunction in Patients With the Metabolic Syndrome.

In patients at high risk for future cardiovascular events, more intensive LDL cholesterol lowering with high doses statin therapy provides greater protection against death or major cardiovascular events than does a standard regimen. Intensive LDL ch...
Full record

US Clinical Trial NCT00296803 – NIH – Feb 23, 2006

PROCLAIM: Pilot Study Examining Effects of Clopidogrel Compared to Placebo on Markers of Inflammation in Subjects With Metabolic Syndrome

No preview available.
Full record

US Clinical Trial NCT00138528 – NIH – Aug 25, 2005

Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome

No preview available.
Full record

US Clinical Trial NCT01367431 – NIH – Mar 15, 2011

Xanthohumol and Metabolic Syndrome

No preview available.
Full record

US Clinical Trial NCT01182844 – NIH – Aug 13, 2010

Obesity - Inflammation - Metabolic Disease: Effect of Lactobacillus Casei Shirota

Obesity and metabolic disorders (type 2 diabetes and insulin resistance) are tightly linked to inflammation. Obesity, a pandemic affecting 30-50% of the adult population, is mediated by a variety of genetic and environmental factors. It is well desc...
Full record

US Clinical Trial NCT01741298 – NIH – Nov 27, 2012

Biobehavioral Bases & Management of Metabolic Syndrome

The metabolic syndrome is increasingly being recognized as a major threat to good health - especially cardiovascular health - and its frequency appears to be increasing in relation to the current epidemic of obesity. The objective of this study is t...
Full record

US Clinical Trial NCT00534183 – NIH – Sep 21, 2007

Metabolic Profile and Anthropometric Changes in Schizophrenia

we aimed to study the effects of antipsychotics, olanzapine, risperidone and haloperidol on development of metabolic syndrome in a drug naïve population suffering from first episode schizophrenia and compared it with a matched healthy control group....
Full record

US Clinical Trial NCT00569764 – NIH – Dec 6, 2007

The Effects of Metabolic Parameters of Aripiprazole in Patients With Schizophrenia

To measure the long-term changes in weight, plasma lipids and fasting blood glucose after switching antipsychotic treatment to aripiprazole, 1 year, open label studies in out and in-patients with schizophrenia. The measurement of weight and lipid p...
Full record

US Clinical Trial NCT01931527 – NIH – Aug 23, 2013

Effect of Plasma Uric Acid on Insulin Sensitivity, Endothelial Function and Inflammation

It has been hypothesized that oxidative stress is involved in the pathogenesis of insulin resistance associated with obesity. Circulating uric acid (UA) is the body's major endogenous plasma antioxidant. Therefore, the investigators evaluated whethe...
Full record
Register to view full records and disable ads.

US Clinical Trial NCT00543985 – NIH – Oct 11, 2007

Exercise in Patients With Metabolic Syndrome and Weight Regain - Echocardiography Substudy

Patients must have 2 of the 5 criteria for metabolic syndrome and be able to exercise in a monitored setting for 45 min 5 times a week.
Full record

US Clinical Trial NCT00171548 – NIH – Sep 12, 2005

Project to Promote the Evaluation of Cardiovascular Risk in Clinical Practice, and Assess Its Evolution After the Implementation of Multifactorial Preventive Strategy Aimed at Reducing the Level of Global Risk (SCORE Algorithm) in Subjects With Metabolic Syndrome and a Risk Level of 5%

No preview available.
Full record

US Clinical Trial NCT01293162 – NIH – Feb 9, 2011

Study on the Role of a Combination of Nutraceuticals (Armolipid Prev) With an Effect on Blood Pressure and Lipids in the Control of Cardiovascular Risk

Study on the role of a combination of nutraceuticals (Armolipid Prev) with an effect on blood pressure and lipids in the control of cardiovascular risk. APv - cpr - 0210 1. Study rationale The strategies for the prevention of cardiovascular diseas...
Full record

US Clinical Trial NCT00395486 – NIH – Nov 1, 2006

A 6-week, Randomised, Open-label, Parallel Group, Multi-centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Metabolic Syndrome Subjects With Raised LDL-C

No preview available.
Full record

US Clinical Trial NCT01770054 – NIH – Jan 15, 2013

Evaluation of the Prevalence of Metabolic Syndrome in Atahualpa Residents Aged 40 Years or More.

Several studies have shown that the occurrence of the metabolic syndrome is a risk factor for the development of cerebrovascular and ischemic heart disease. To evaluate the prevalence of the metabolic syndrome, we will invite all Atahualpa residents...
Full record

US Clinical Trial NCT01176630 – NIH – Aug 4, 2010

Prevalence of Metabolic Syndrome in a Maintenance Hemodialysis Population

Risk factors for metabolic syndrome will be collected for each consented patient. They include elevated serum triglycerides, reduced HDL cholesterol, hypertension, elevated fasting blood sugar concentration and abdominal obesity. The investigator wi...
Full record

US Clinical Trial NCT00666848 – NIH – Apr 23, 2008

Effect of Sitagliptin on the Blood Pressure Response to ACE Inhibition in the Metabolic Syndrome

The prevalence of metabolic syndrome and Type 2 diabetes mellitus (T2DM) has reached epidemic proportions in developed countries and is closely associated with hypertension. As new oral hypoglycemic agents become available for clinical use, practiti...
Full record

US Clinical Trial NCT01705678 – NIH – Apr 12, 2012

An Investigation Into the Effects of Krill Oil vs. Fish Oil on Markers of Cardiovascular Disease in Males With Metabolic Syndrome

No preview available.
Full record

US Clinical Trial NCT00300365 – NIH – Mar 6, 2006

A Randomized, Double Blind, Placebo Controlled Trial of Pioglitazone and Niacin Extended Release in Non-diabetic Patients With Metabolic Syndrome

This is a two-arm, parallel, double-blind randomized prospective clinical trial. The subjects will be asked to provide informed consent, and then undergo screening for enrollment criteria at the first visit (-5 weeks). The subjects who are eligible,...
Full record

US Clinical Trial NCT00605436 – NIH – Jan 16, 2008

Restorative Yoga for Therapy of the Metabolic Syndrome: A Pilot Trial

Study Interventions: There will be a 12-week intervention period. 1. Yoga Therapy Group: Those randomized to yoga therapy will receive twice-weekly group yoga sessions at the Osher Center for the entire intervention period. The yoga postures and br...
Full record
Register to view full records and use our APIs.

US Clinical Trial NCT01785615 – NIH – Feb 1, 2013

Interactions of Thrombogenic, Lipogenic, and Inflammatory Markers in Women With the Metabolic Syndrome - Effect of Atorvastatin

The first phase of the study is an observational phase as previously described. The second phase was a prospective evaluation of the effect of a well known "statin" drug (Lipitor) on different biochemical factors measured in the blood. The eligible...
Full record

US Clinical Trial NCT03708549 – NIH – Oct 13, 2018

Comparison of the Efficacy and Safety of Berberine and Metformin for Schizophrenia Patients With Metabolic Syndrome

No preview available.
Full record

US Clinical Trial NCT03445741 – NIH – Feb 11, 2018

Effects of Different Intensities and Durations of Aerobic Exercise Training and Detraining on Metabolic, Hormonal Responses and Abdominal Obesity in Women With Metabolic Syndrome.

Objective: To show metabolic and hormonal responses and effects on abdominal obesity of aerobic exercise in different intensity and duration and detraining period in women with metabolic syndrome. Methods: Fifty-one women with metabolic syndrome we...
Full record

US Clinical Trial NCT00748787 – NIH – Sep 8, 2008

Multicenter, Double Blind, Randomized, Controlled With Placebo, to Evaluate the Effect of the Treatment With Plantago Ovata Husk in the Incidence of the Remission of Metabolic Syndrome in Children and Adolescents Between 10 to 16 Years Old.

The prevalence of the metabolic syndrome is increasing in the last decade as well in adult people as in children and adolescents. The early diagnosis and treatment measures could be very important in order to reduce the cardiovascular risk in such p...
Full record

US Clinical Trial NCT01755104 – NIH – Dec 18, 2012

A Randomized Double-blind Placebo Controlled Trial on the Effect of Stablor™ on the Abdominal Visceral Fat Mass Loss in Patients With a Metabolic Syndrome

No preview available.
Full record

US Clinical Trial NCT02008838 – NIH – Dec 8, 2013

No preview available.
Full record

US Clinical Trial NCT01668888 – NIH – Aug 14, 2012

No preview available.
Full record

US Clinical Trial NCT02497352 – NIH – Jul 10, 2015

No preview available.
Full record

US Clinical Trial NCT01718431 – NIH – Oct 9, 2012

Prebiotics as Means to Modulate Colonic Events, With the Purpose to Increase Beneficial Effects on Metabolism, Satiety and Cognition.

No preview available.
Full record

US Clinical Trial NCT02912325 – NIH – Sep 12, 2016

A Pilot, Non-Comparative Study to Assess the Efficacy and Safety of the New Food Supplement FaseMETS in Metabolic Syndrome

The trial is designed as a multicenter, open label, non-comparative, 6 months, pilot study. The primary objective is to evaluate the efficacy of FaseMetS ® administered for 6 months treatment combined with a health management plan in reducing the s...
Full record
Register to view full records and receive email notifications.

US Clinical Trial NCT02623777 – NIH – Nov 28, 2015

Evaluation of the Effect of Arabinoxylan Oligosaccharides Consumption on Insulin Resistance in Patients With Metabolic Syndrome and the Contribution of Short-chain Fatty Acids Production

No preview available.
Full record

US Clinical Trial NCT03435315 – NIH – Jan 23, 2018

Treadmill Exercise in Metabolic Syndrome

No preview available.
Full record

US Clinical Trial NCT03534024 – NIH – May 11, 2018

The Effects of Nanomicelles Curcumin on Glycemic Control, Serum Lipid Profile ,Blood Pressure and Anthropometric Measurements in Patients With Metabolic Syndrome

No preview available.
Full record

US Clinical Trial NCT03883685 – NIH – Mar 11, 2019

The Effect of Probiotics on Obesity. Metabolic Endotoxemia and Inflammation

General Objective: To study the relatedness of obesity, with the associated metabolic endotoxemia and low-grade inflammation, and the effectiveness of probiotics intervention in adults, in UAE. Specific Aims: - Investigate the link between metabo...
Full record

US Clinical Trial NCT03267901 – NIH – Aug 14, 2017

Effects of Daily Walnut Intake Among the Subjects With Metabolic Syndrome in South Korea

No preview available.
Full record

US Clinical Trial NCT00574834 – NIH – Dec 13, 2007

Mechanisms of Reduced Ramipril on the Onset of Type 2 Diabetes Mellitis

Several studies have demonstrated that therapeutic agents used to reduce glucose levels and/or weight can delay the onset of type 2 diabetes. Intriguingly, angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) also re...
Full record

US Clinical Trial NCT01007227 – NIH – Nov 2, 2009

Achievement of Dietetic and Exercise Therapy Evaluated by Self-assessment Score Significantly Improved Endothelial Dysfunction in Patients With Metabolic Syndrome

Outline of methods RH-PAT was measured in high-risk patients under 70 years old. The MetSyd was defined according to guidelines of the National Cholesterol Education Program Third Adult Treatment Panel (NCEP - ATP III). We instructed all MetSyd pati...
Full record

US Clinical Trial NCT00929500 – NIH – Jun 26, 2009

The Effect of Mixed Aerobic and Strength Training Program on Physical Fitness and Cerebrovascular Function in Older Women With Metabolic Syndrome: A Pilot Study With Randomized Control Trial (RCT) Design

Metabolic syndrome is a cluster of conditions and disorders that increase the risk for coronary artery disease (CAD) and strokes. Sedentary lifestyle is one of the risk factors, which decrease overall physical fitness and together with aging may lea...
Full record

US Clinical Trial NCT01224743 – NIH – Oct 14, 2010

Effect of Fruit and Vegetable Concentrates on Endothelial Function in Persons With Metabolic Syndrome: A Randomized, Controlled, Crossover Trial

No preview available.
Full record

US Clinical Trial NCT01099306 – NIH – Apr 5, 2010

Pharmacist - Physician Collaborative Approach to the Management of Metabolic Syndrome

A single blinded prospective randomized controlled trial conducted in family medicine outpatients clinics in Jordan. The study enrolled 199 patients met the National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATPIII) criteria for...
Full record
Register to view full records and advanced analytics.

US Clinical Trial NCT00750308 – NIH – Sep 5, 2008

Renin Angiotensin Aldosterone System (RAAS) and Fibrinolysis in Humans: ACEi

No preview available.
Full record

US Clinical Trial NCT01360268 – NIH – May 24, 2011

The Metabolic Profile and Adipocytokine Alterations of Patients With HCV Infection Before and After HCV Therapy"

Subjects with chronic hepatitis C infections will be enrolled Inclusion Criteria 1. Aged 18 y/o or older 2. Positive for the HCV antibody and HCV RNA detected 3. Patients with abnormal liver function OR a liver biopsy specimen taken in the 6 mon...
Full record

US Clinical Trial NCT01463748 – NIH – Oct 31, 2011

No preview available.
Full record

US Clinical Trial NCT01928355 – NIH – Aug 20, 2013

No preview available.
Full record

US Clinical Trial NCT02034136 – NIH – Jul 21, 2013

Effects of Ginsenoside Supplementation on Insulin Resistance and Cardiometabolic Risk Factors in Men With Metabolic Syndrome: a Randomized Controlled Trial.

Methods : A randomized, double-blind, placebo-controlled, single-center study in 60 subjects who are not taking drugs that could affect metabolic and vascular function. Subjects will be randomized into a Korean red ginseng (3.0g/d) group or placebo...
Full record

US Clinical Trial NCT00673023 – NIH – May 4, 2008

Study the Role of Polymorphism at the CETP Gene Locuse in the Determining Lipid Profile Response to Dietary Change

No preview available.
Full record

US Clinical Trial NCT03737422 – NIH – Oct 11, 2018

Evaluation of the Effects of Hesperidin and Flaxseed Supplementation in Patients With Metabolic Syndrome

No preview available.
Full record

US Clinical Trial NCT03734874 – NIH – Oct 11, 2018

Evaluation of the Effects of Hesperidin Supplementation in Patients With Metabolic Syndrome

No preview available.
Full record

US Clinical Trial NCT03514667 – NIH – Apr 20, 2018

The Effects of Nanomicielle Curcumin on Oxidative Stress, Systemic Inflammation, Adiponectin in Serum and NF-kB in Blood Mononuclear Cells, in Patients With Metabolic Syndrome

No preview available.
Full record